Skip to main content
All inhalers

BREZTRI AEROSPHERE

Budesonide/Glycopyrrolate/Formoterol

BREZTRI AEROSPHERE

ICSLAMALABA MDI

Budesonide / Glycopyrrolate / Formoterol fumarate · AstraZeneca

Clinical Reference

Active Medication & Mechanism

  • Budesonide ICS
    160 mcg per actuation

    Corticosteroid with potent anti-inflammatory activity. Reduces airway inflammation through suppression of inflammatory cells and mediators.

  • Glycopyrrolate LAMA
    9 mcg per actuation

    Long-acting muscarinic antagonist. Blocks M3 receptors on airway smooth muscle, inhibiting cholinergic bronchoconstriction.

  • Formoterol fumarate LABA
    4.8 mcg per actuation

    Long-acting beta2-adrenergic agonist with rapid onset. Produces sustained bronchodilation via beta2-receptor stimulation.

FDA-Approved Dosing by Indication

// approval varies by strength + age
COPD
1/1 approved regimens
  • 160/9/4.8 mcg FDA Approved
    Pop · Adults (≥18 years)
    2 inhalations twice daily (morning and evening)
    Maintenance treatment of COPD. Triple therapy (ICS/LAMA/LABA) in a single inhaler for patients on LAMA/LABA who require additional ICS, or on ICS/LABA who require additional LAMA.
    Total · 640/36/19.2 mcg
Asthma
0/1 approved regimens
  • Any strength Not Approved
    Pop · All patients
    Total · Breztri Aerosphere is NOT indicated for asthma.
Acute Use
0/1 approved regimens
  • Any strength Not Approved
    Pop · Acute bronchospasm / rescue
    Total · Not for acute bronchospasm. Use a SABA.

For clinical reference only. This workspace is intended for use by qualified healthcare professionals and is not a substitute for clinical judgement, prescribing information, or product monographs. Always verify doses and indications against the most current labelling before prescribing.

Inhaler Database · © inhalerdatabase.com 2024–2026 — All rights reserved